Key result
Clinical-biomarker gradient boosting model predicts Kawasaki disease coronary lesion risk with ~0.79 validation AUC.
Why the study?
A predictive model integrating multidimensional clinical indicators and laboratory biomarkers was needed for the early and precise assessment of coronary artery lesion risk in Kawasaki disease.
Does a clinical-biomarker fusion model accurately predict the development of coronary artery lesions in children with Kawasaki disease?
Does a clinical-biomarker fusion model accurately predict the development of coronary artery lesions in children with Kawasaki disease?
A machine learning model integrating clinical and biomarker data accurately predicts the risk of coronary artery lesions in children with Kawasaki disease, providing a tool for early identification and intervention.
Supports timely intervention for high-risk Kawasaki disease; extends traditional models via clinical-biomarker machine learning but remains hypothesis-generating.
This study aimed to develop and validate a predictive model integrating multidimensional clinical indicators and laboratory biomarkers for the early and precise assessment of coronary artery lesion (CAL) risk in Kawasaki disease. A retrospective analysis was conducted on 320 children with Kawasaki disease admitted between January 2020 and June 2024. The sample size was calculated using PASS 2021 software (α = 0.05, 1-β = 80%), with post-hoc power exceeding 85%. Patients were randomly allocated into a training set (n = 224) and a validation set (n = 96) in a 7:3 ratio. In the training set, univariate analysis identified CAL-associated indicators (P < 0.05). Least Absolute Shrinkage and Selection Operator (LASSO) regression was used for variable compression and feature selection. The core variables were incorporated into a multivariate logistic regression to identify independent risk factors. Based on these factors, three machine learning models—Gradient Boosting Machine (GBM), Support Vector Machine (SVM), and Convolutional Neural Network (CNN)—were constructed. Model performance was evaluated using the AUC, calibration curves, and DCA. Interpretability was analyzed using SHapley Additive exPlanations (SHAP) values. No significant differences in baseline characteristics were observed between the training and validation sets (P > 0.05). Univariate analysis identified seven significant indicators. LASSO regression refined these to five core variables. Multivariate logistic regression confirmed all five as independent risk factors for CAL (P < 0.05). Among the machine learning models, the GBM model demonstrated superior performance, with AUC of 0.872 (95% CI: 0.798–0.945) in the training set and 0.790 (95% CI: 0.623–0.957) in the validation set. Calibration curves were closest to the ideal line. DCA indicated net clinical benefit across a wide threshold probability range. SHAP analysis provided intuitive prediction interpretability. An integrated clinical-biomarker model was developed and validated for the early prediction of CAL in Kawasaki disease. The model demonstrates good discriminative ability, calibration, and clinical utility. and provides a promising tool for the early identification of high-risk children and the optimization of intervention strategies. Not applicable.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question. A Gradient Boosting Machine model integrating clinical and biomarker variables predicted coronary artery lesion risk in Kawasaki disease with an AUC of 0.872 in training and 0.790 in validation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: